Czech and Slovak Ophthalmology 490 Original article Pharmacological Treatment of Glaucoma and Biomechanical Properties of the Cornea Liehneová Ivana Karlovská Soňa 17 9 2014 5 1

Purpose: To evaluate and compare the impact of the long-term use of medication to reduce intraocular pressure on the biomechanical properties of the cornea. Material and methods: A study sample of 305 eyes of 154 patients newly diagnosed with primary open angle glaucoma (POAG, n = 68) or ocular hypertension (OH, n = 6) was included in a prospective cohort study. The control group comprised 80 untreated eyes of 40 patients with ocular hypertension and 80 eyes of 40 patients with no ocular pathology. The following parameters were evaluated: intraocular pressure (IOPg, IOPcc), hysteresis (CH), corneal resistance factor (CRF) and central corneal thickness (CCT). The parameters were evaluated at baseline (untreated) and at follow-up intervals of 3, 6, 9 and 12 months. The same schedule was used for the eyes in the control group. Eyes with POAG or OH were divided into two sub-groups, depending on the type of applied medication: prostaglandin analogues, carboanhydrase inhibitors alone or in combination with beta-blockers. Results: We did not demonstrate any statistically significant difference in hysteresis in patients with newly diagnosed POAG (as yet untreated) in comparison with the normal eyes in the control group (p = 0.238). We demonstrated significantly higher values of CRF (p = 0.032) and CCT (p = 0.013) in the control group of untreated patients with ocular hypertension. This result confirms a higher number of patients with stiffer and thicker corneas. A statistically significant difference of CH and CRF was demonstrated (p < 0.0001) in eyes treated by prostaglandin analogues during the follow up period. In these eyes we also demonstrated a reduction of CCT (p < 0.001). We did not record any other statistically significant change in the remaining observed parameters. Conclusion: The increase in CH and CRF may demonstrate a change of the biomechanical properties of the cornea following the long-term use of prostaglandin analogues. The biomechanical properties of the cornea were not impacted upon by carboanhydrase inhibitors. Further studies are required in order to establish the effect of the long-term use of prostaglandin analogues on the accuracy of IOP measurements.

 glaucoma intraocular pressure cornea hysteresis central corneal thickness References Randleman JB.: Post-laser in-situ keratomileusis ectasia: current understanding and future directions. Curr Opin Ophthalmol, 2006 Aug; 17(4): 406–12. Shah S, Laiquzzaman M., Bhojwani R, Mantry S.: Assessment of the Biomechanical properties of the Cornea with the Ocular Response Analyzer in Normal and Keratoconic Eyes. IOVS, 2007 July; Vol. 48, No.7. Liu R, Chu RY, Zhou XT, Qu XM, Dai JH, Wang L.: A compare study on cornea biomechanical properties in normal and keratoconic eyes. Zhonghua Yan Ke Za Zhi, 2009 Jun; 45(6): 509–13. Schweitzer C, Roberts CJ, Mahmoud AM, Colin J, Maurice-Tison S, Kerautret J.: Screening of forme fruste keratoconus with the ocular response analyzer. Invest Ophthalmol Vis Sci, 2010 May; 51(5): 2403-10. doi: 10.1167/iovs.09-3689.10.1167/iovs.09-3689 Congdon NG, Broman AT, Bandeen- -Roche K, Grover D, Quigley HA.: Central corneal thickness and corneal hysteresis associated with glaucoma damage. Am J Ophthalmol, 2006 May; 141(5): 868–75. Downs JC, Suh JK, Thomas KA, Bellezza AJ, Hart RT, Burgoyne CF.: Viscoelastic material properties of the peripapillary sclera in normal and early-glaucoma monkey eyes. Invest Ophthalmol Vis Sci, 2005 Feb; 46(2): 540–6. Burgoyne CF, Downs JC, Bellezza AJ, Suh JK, Hart RT.: Optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog Retin Eye Res, 2005; 24: 39–73. Jonas JB.: Role of cerebrospinal fluid pressure in the pathogenesis of glaucoma. Acta Ophthalmol, 2011; 89: 505–14. Wu KY, Wang HZ, Hong SJ.: Effect of latanoprost on cultured porcine corneal stromal cells. Curr Eye Res, 2005 Oct; 30(10): 871–9. Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN.: Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol, 1999 Jun;117(6): 794–801. Inoue K, Okugawa K, Oshika T, Amano S.: Influence of Dorzolamide on Corneal Endothelium. Jpn J Ophthalmol, 2003; 47: 129–133. Mietz H., Schrehardt U., Strassfeld C., Krieglstein GK.: Effect of latanoprost and timolol on the histopathology of the rabbit conjunctiva. IOVS, 2001 Mar; 42(3): 679–87. Baudouin Ch., De Lunardo Ch.: Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol, 1998; 82, 39–42. Ishibashi T, Yokoi N, Kinoshita S.: Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma, 2003 Dec; 12(6): 486-90. Liehneová I.: Farmakoterapie glaukomu. Čes a Slov Oftalmol, 2010 Oct; 66(4): 155–8. Wirtitsch MG, Findl O, Heinzl H.: Effect of Dorzolamide Hydrochloride on Central Corneal Thickness in Humans with Cornea Guttata. Arch Ophthalmol, 2007, 125; (10): 1345-1350. Zhao JC, Chen T.: Brinzolamide induced reversible corneal decompensation. Br J Ophthalmol, 2005 Mar; 89(3): 389-90. March WF, Ochsner KI.: The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. Am J Ophthalmol. 2000 Feb; 129(2): 136–43.2004. Iester M, Telani S, Brusini P, Rolle T, Fogagnolo P, Martini E, Milano G, Paoli D.: Italian Central corneal thickness and glaucoma treatment: an Italian multicenter cross-sectional study. Glaucoma Register. J Ocul Pharmacol Ther, 2013 Jun; 29(5): 469–73. Miglior S,Albe E, Guareschi M, et al.: Intraobserver and interobserver reproducibility in the evaluation of ultrasonic pachymetry measurements of central corneal thickness, Br J Ophthalmol, 2004; 88: 174–7. Bagga H, Liu JH, Weinreb RN.: Intraocular pressure measurements throughout the 24 h. Curr Opin Ophthalmol, 2009 Mar; 20(2): 79–83. Gaton DD, Sagara T., Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN.: Increased matrix metalloproteinases 1,2 and 3 in monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch Ophthalmol, 2001 Aug; 119(8): 1165–70. Hatanaka M., Vessani R., Elias I., Morita C., Susanna R.: The effect of Prostaglandin Analogs and Prostamide on Central Corneal Thickness. J. Ocular Pharmacology and Therapeutics, 2009; 25: 51–53. Liu Y., Yanai R., Lu Y., Hirano S., Sagara T., Nishida T.: Effects of antiglaucoma drugs on collagen gel contraction mediated by human corneal fibroblasts. J Glaucoma, 2006 Jun; 15(3): 255–9. Viestenz A, Martus P, Schlötzer-Schrehardt U, Langenbucher A, Mardin CY.: Impact of prostaglandin-F (2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness - a cross-sectional study on 403 eyes. Klin Monbl Augenheilkd, 2004 Sep; 221(9): 753–6. Schlote T, Tzamalis A, Kynigopoulos M.: Central corneal thickness during treatment with travoprost 0.004% in glaucoma patients. J. Ocul Pharmacol Therap, 2009; 25: 459–4662. Zhong Y, Shen X, Yu J, Tan H, Cheng Y. : The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness. Cornea, 2011 Aug; 30(8): 861–4. Bafa M., Georgopoulos G., Mihas C., Stavrakas P., Papaconstatinou, Vergados I.: The effect of prostaglandin analogues on central corneal thickness of patients with chronic open-angle glaucoma: a 2year study on 129 eyes. Acta Ophthalmol, 2011; 89: 448–451. Sun L, Shen M, Wang J, Fang A, Xu A, Fang H, Lu F.: Recovery of corneal hysteresis after reduction of intraocular pressure in chronic primary angle-closure glaucoma. Am J Ophthalmol, 2009 Jun; 147(6): 1061–6. Shimmyo M.: Recovery of corneal hysteresis after reduction of intraocular pressure in chronic primary angle-closure glaucoma. Am J Ophthalmol, 2009; 148: 623. Agarwal DR, Ehrlich JR, Shimmyo M, Radcliffe NM.: The relationship between corneal hysteresis and the magnitude of intraocular pressure reduction with topical prostaglandin therapy. Br J Ophthalmol, 2012 Feb; 96(2): 254–7. Rouse EJ, Roberts CJ, Mahmoud AM.: The Measurement of Biomechanical Parameters as a Function of Peak Applied Pressure in the Reichert Ocular Response Analyzer. IOVS, 2007; 48: ARVO E- -Abstract 1247. Congdon NG, Broman AT, Bandeen- -Roche K, Grover D, Quigley HA.: Central corneal thickness and corneal hysteresis associated with glaucoma damage. Am J Ophthalmol, 2006, May; 141(5): 868–75. Glass DH, Roberts CJ, Litsky AS, Weber PA.: A viscoelastic biomechanical model of the cornea describing the effect of viscosity and elasticity on hysteresis. Invest Ophthalmol Vis Sci, 2008 Sep; 49(9): 3919–26.